A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of AZD0780 in Participants With Dyslipidaemia
← catalyst calendarNCT06834932 · readout in 187 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2/3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · Triple · Treatment
Enrollment
432actual
Sites
43
Countries
China, Hong Kong
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2024-12-06 | actual | When the study began enrolling |
| Primary completion | 2027-02-22 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2027-02-22 | estimated | The whole study's end, after follow-up |
| First posted | 2025-02-19 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-11 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Dyslipidaemia
Interventions
- Drug: Placebo
- Drug: Rosuvastatin Dose 1
- Drug: Rosuvastatin dose 2
- Drug: AZD0780
Primary outcomes
what the primary-completion date above is the date OFAZD0780 Concentrations in plasma (PART A)
measured Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)
AZD0780 PK Parameter: AUC0-t (PART A, intensive PK subgroup).
measured Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)
AZD0780 PK parameter: Cmax (PART A, intensive PK subgroup)
measured Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)
AZD0780 PK parameter: AUCtau (PART A, intensive PK sub group)
measured Day 1 and Day 8: Pre-dose, 0.25,0.5,1,1.5,2,3,4,6,8,12,16 hours post-dose. Day 2, Day 9, Day 11, Day 15, Day 22, Day 29: Pre-dose (PART A)
Relative change in LDL-C from baseline to 12 weeks (PART B)
measured From baseline to 12 weeks (PART B)
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed